Ronald Levy

List of Publications by Citations

213 papers	17,080 citations	52 h-index	130 g-index
222 ext. papers	19,632 ext. citations	6.8 avg, IF	6.26 L-index

#	Paper	IF	Citations
213	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *New England Journal of Medicine*, **2017**, 377, 2531-2544	59.2	2326
212	Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nature Medicine*, **1996**, 2, 52-8	50.5	1576
211	IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma. *Blood*, **1997**, 90, 2188-2195	2.2	1371
210	Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *Journal of Clinical Oncology*, **2003**, 21, 3940-7	2.2	1112
209	Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. *New England Journal of Medicine*, **1982**, 306, 517-22	59.2	817
208	Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. *Blood*, **2010**, 115, 2578-85	2.2	612
207	Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. *New England Journal of Medicine*, **1992**, 327, 1209-15	59.2	485
206	Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma Long-Term Results of a Clinical Trial. *Blood*, **1997**, 89, 3129-3135	2.2	419
205	Dendritic cell vaccines for cancer immunotherapy. *Annual Review of Medicine*, **1999**, 50, 507-29	17.4	391
204	In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. *Journal of Clinical Oncology*, **2010**, 28, 4324-32	2.2	376
203	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E966-72	11.5	295
202	Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. *Nature*, **1993**, 362, 755-8	50.4	293
201	Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. *Journal of Clinical Investigation*, **2013**, 123, 2447-63	15.9	285
200	Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. *Blood*, **2001**, 98, 945-51	2.2	251
199	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1116-25	11.5	232
198	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. *Science Translational Medicine*, **2016**, 8, 364ra155	17.5	231
197	DNA immunization induces protective immunity against B-cell lymphoma. *Nature Medicine*, **1996**, 2, 1038-41	50.5	227

196	Eradication of spontaneous malignancy by local immunotherapy. *Science Translational Medicine*, **2018**, 10,	17.5	212
195	Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. *Blood*, **2003**, 101, 3109-17	2.2	196
194	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. *Blood*, **2015**, 125, 3679-87	2.2	190
193	Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 8886-91	11.5	190
192	Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. *Blood*, **2001**, 98, 1352-7	2.2	189
191	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. *Clinical Cancer Research*, **2017**, 23, 1929-1936	12.9	181
190	Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. *Blood*, **2013**, 122, 981-7	2.2	173
189	CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. *Blood*, **2011**, 117, 2423-32	2.2	170
188	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*, **2018**, 36, 2845-2853	2.2	164
187	Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. *Nature*, **2017**, 543, 723-727	50.4	161
186	Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. *Cancer*, **1978**, 42, 2379-91	6.4	152
185	T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. *Blood*, **2009**, 113, 3546-52	2.2	144
184	Anti-Idiotype Antibodies Can Induce Long-Term Complete Remissions in Non-Hodgkin's Lymphoma Without Eradicating the Malignant Clone. *Blood*, **1998**, 92, 1184-1190	2.2	144
183	Targeting CD137 enhances the efficacy of cetuximab. *Journal of Clinical Investigation*, **2014**, 124, 2668-82	15.9	137
182	A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. *Clinical Cancer Research*, **2008**, 14, 6697-703	12.9	133
181	High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. *Blood*, **2013**, 121, 1367-76	2.2	131
180	Predicting HLA class II antigen presentation through integrated deep learning. *Nature Biotechnology*, **2019**, 37, 1332-1343	44.5	112
179	Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. *Journal of Immunology*, **2007**, 179, 2493-500	5.3	106

178	Current clinical trials testing combinations of immunotherapy and radiation. *Seminars in Radiation Oncology*, **2015**, 25, 54-64	5.5	103
177	Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. *Blood*, **2009**, 114, 3431-8	2.2	101
176	Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. *Blood*, **2007**, 109, 3393-9	2.2	101
175	Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. *Hybridoma*, **1985**, 4, 191-209		101
174	Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5? noncoding regulatory region of the BCL-6 gene. *Blood*, **2000**, 96, 635-639	2.2	82
173	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. *Blood*, **2008**, 111, 5509-14	2.2	80
172	Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. *Cell Stem Cell*, **2018**, 22, 501-513.e7	18	78
171	Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. *Cancer Discovery*, **2018**, 8, 1258-1269	24.4	78
170	Imaging activated T cells predicts response to cancer vaccines. *Journal of Clinical Investigation*, **2018** , 128, 2569-2580	15.9	74
169	Combination strategies to enhance antitumor ADCC. *Immunotherapy*, **2012**, 4, 511-27	3.8	71
168	Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. *Biotechnology and Bioengineering*, **2005**, 89, 503-11	4.9	66
167	DNA fragmentation and cell death mediated by T cell antigen receptor/CD3 complex on a leukemia T cell line. *European Journal of Immunology*, **1989**, 19, 1911-9	6.1	63
166	Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. *International Journal of Cancer*, **2009**, 124, 239-44	7.5	61
165	mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E9153-E9161	11.5	60
164	Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. *Journal of Clinical Oncology*, **2014**, 32, 1797-803	2.2	59
163	Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. *Blood*, **2015**, 125, 2079-86	2.2	54
162	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. *Blood*, **2017**, 129, 759-770	2.2	52
161	Idiotype Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formulations. *Blood*, **1997**, 90, 3699-3706	2.2	52

160	Local Delivery of , , and mRNA Kindles Global Anticancer Immunity. *Cancer Research*, **2019**, 79, 1624-1634	10.1	50
159	Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. *Trends in Immunology*, **2011**, 32, 510-6	14.4	50
158	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. *Cancer Immunology Research*, **2019**, 7, 355-362	12.5	49
157	Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. *Cancer Research*, **2015**, 75, 4517-26	10.1	49
156	Mutation analysis of the 5? noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity. *Blood*, **2000**, 95, 1400-1405	2.2	49
155	Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. *Blood*, **2009**, 113, 5743-6	2.2	47
154	The optimal application of forward and ninety-degree light scatter in flow cytometry for the gating of mononuclear cells. *Cytometry*, **1985**, 6, 401-6		46
153	Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. *Blood*, **2019**, 133, 1119-1129	2.2	45
152	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. *Clinical Cancer Research*, **2018** , 24, 870-881	12.9	45
151	Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. *Clinical Cancer Research*, **2013**, 19, 5261-3	12.9	44
150	Quantitation and estimation of lymphocyte subsets in tissue sections. Comparison with flow cytometry. *American Journal of Clinical Pathology*, **1987**, 87, 470-7	1.9	44
149	CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. *American Journal of Pathology*, **2012**, 181, 795-803	5.8	42
148	Translational medicine in action: anti-CD20 therapy in lymphoma. *Journal of Immunology*, **2014**, 193, 1519-24	5.3	41
147	A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 14526-31	11.5	39
146	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. *European Journal of Cancer*, **2020**, 136, 4-6	7.5	37
145	Joint modeling and registration of cell populations in cohorts of high-dimensional flow cytometric data. *PLoS ONE*, **2014**, 9, e100334	3.7	37
144	A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.. *Journal of Clinical Oncology*, **2014**, 32, 3007-3007	2.2	36
143	A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. *Blood*, **2011**, 117, 118-27	2.2	35

142	Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. *Leukemia and Lymphoma*, **2009**, 50, 37-46	1.9	35
141	Intratumoral Immunotherapy for Early-stage Solid Tumors. *Clinical Cancer Research*, **2020**, 26, 3091-3099	12.9	31
140	Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. *International Reviews of Immunology*, **1989**, 4, 251-70	4.6	28
139	Epstein-Barr virus-positive follicular lymphoma. *Modern Pathology*, **2017**, 30, 519-529	9.8	26
138	Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. *Blood Advances*, **2018**, 2, 2230-2241	7.8	26
137	B-cell lymphomas present immunoglobulin neoantigens. *Blood*, **2019**, 133, 878-881	2.2	25
136	Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 1613-8	11.5	23
135	CD81 as a tumor target. *Biochemical Society Transactions*, **2017**, 45, 531-535	5.1	22
134	Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. *OncoImmunology*, **2012**, 1, 957-958	7.2	22
133	Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. *American Journal of Hematology*, **2020**, 95, 510-520	7.1	20
132	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 Non-Hodgkin Lymphomas. *Clinical Cancer Research*, **2020**, 26, 2524-2534	12.9	20
131	Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells. *Biochemical and Biophysical Research Communications*, **2009**, 390, 971-6	3.4	20
130	Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. *British Journal of Haematology*, **2008**, 141, 69-72	4.5	18
129	A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma. *Genes Chromosomes and Cancer*, **1993**, 6, 140-50	5	18
128	Production in vitro of murine antibody to a human histocompatibility alloantigen. *Nature*, **1978**, 271, 461-2	50.4	18
127	Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. *Scientific Reports*, **2018**, 8, 2278	4.9	16
126	A roadmap for discovery and translation in lymphoma. *Blood*, **2015**, 125, 2175-7	2.2	16
125	Cancer vaccines: pessimism in check. *Nature Medicine*, **2004**, 10, 1279; author reply 1279-80	50.5	16

124	A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL.. *Journal of Clinical Oncology*, **2015**, 33, 3004-3004	2.2	15
123	Immunomodulating antibodies and drugs for the treatment of hematological malignancies. *Cancer and Metastasis Reviews*, **2011**, 30, 97-109	9.6	14
122	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia **2016**, 4, 90		14
121	CD81 is a novel immunotherapeutic target for B cell lymphoma. *Journal of Experimental Medicine*, **2019**, 216, 1497-1508	16.6	13
120	Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 5376-81	11.5	13
119	Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. *Blood Advances*, **2020**, 4, 4244-4255	7.8	12
118	Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*, **2020**, 38, 1664-1675	2.2	10
117	T-Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins. *Proteomics*, **2018**, 18, e1700410	4.8	10
116	CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.. *Blood Cancer Discovery*, **2022**,	7	10
115	New insights into the mechanism of action of immune checkpoint antibodies. *OncoImmunology*, **2014**, 3, e954869	7.2	9
114	Idiotype vaccination for lymphoma: moving towards optimisation. *Leukemia and Lymphoma*, **2009**, 50, 1-2	1.9	9
113	Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. *Immunotherapy* , **2009**, 1, 809-24	3.8	9
112	Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma. *Leukemia and Lymphoma*, **2003**, 44, 1317-23	1.9	9
111	Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. *Blood*, **2021**, 137, 2869-2880	2.2	9
110	Cancer vaccines and T cell therapy. *Biology of Blood and Marrow Transplantation*, **2013**, 19, S97-S101	4.7	8
109	Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma. *American Journal of Clinical Pathology*, **2010**, 134, 278-81	1.9	8
108	Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity. *Blood*, **2013**, 122, 373-373	2.2	8
107	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. *Journal of Experimental Medicine*, **2020**, 217,	16.6	8

106	An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. *ACS Central Science*, **2021**, 7, 1191-1204	16.8	8
105	Targeting the tetraspanin CD81 reduces cancer invasion and metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	8
104	Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis. *OncoImmunology*, **2016**, 5, e1120399	7.2	8
103	Survival in Follicular Lymphoma: The Stanford Experience, 1960–2003.. *Blood*, **2007**, 110, 3428-3428	2.2	7
102	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. *Blood*, **2016**, 128, 1089-1089	2.2	7
101	A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).. *Journal of Clinical Oncology*, **2013**, 31, TPS3107-TPS3107	2.2	7
100	Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.. *Journal of Clinical Oncology*, **2014**, 32, 3017-3017	2.2	7
99	The Number of CD25+ Tumor-Infiltrating Cells May Predict Clinical Response to Rituximab in Follicular Lymphoma Patients.. *Blood*, **2004**, 104, 748-748	2.2	6
98	Long-Term Follow-Up of Patients Treated in a Phase 2 Trial with MyVax® Personalized Immunotherapy (Recombinant Id-KLH with GM-CSF) after Chemotherapy as Initial Treatment for Follicular Non-Hodgkin Lymphoma (NHL).. *Blood*, **2005**, 106, 2438-2438	2.2	6
97	Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA. *Blood*, **2016**, 128, 1752-1752	2.2	6
96	A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.. *Journal of Clinical Oncology*, **2013**, 31, TPS3108-TPS3108	2.2	6
95	How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. *Blood Cancer Discovery*, **2021**, 2, 562-567	7	6
94	A polymorphism in the BCL-6 gene is associated with follicle center lymphoma. *Leukemia and Lymphoma*, **2001**, 42, 1343-50	1.9	5
93	Homogeneous antibodies directed against human cell surface antigens: I. The mouse spleen fragment culture response to T and B cell lines derived from the same individual. *Journal of Supramolecular Structure*, **1977**, 6, 441-8		5
92	A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin Lymphoma.. *Blood*, **2004**, 104, 3279-3279	2.2	5
91	SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial. *Blood*, **2016**, 128, 2974-2974	2.2	5
90	Abstract 2941: Local tumor irradiation combined with PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series **2014**,		4
89	Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing. *Blood*, **2019**, 134, 297-297	2.2	4

88	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma **2020**, 8,		3
87	Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma. *Blood*, **2020**, 136, 48-48	2.2	3
86	A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma.. *Blood*, **2005**, 106, 778-778	2.2	3
85	Tumor-Infiltrating T Cells Are Not Predictive of Clinical Outcome in Follicular Lymphoma.. *Blood*, **2006**, 108, 824-824	2.2	3
84	Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma. *Blood*, **2012**, 120, 582-582	2.2	3
83	Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy. *Blood*, **2015**, 126, 2748-2748	2.2	3
82	Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity.. *Journal of Clinical Oncology*, **2013**, 31, 3015-3015	2.2	3
81	Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.. *Journal of Clinical Oncology*, **2015**, 33, TPS8604-TPS8604	2.2	3
80	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. *Blood*, **2017**, 130, 826-826	2.2	3
79	A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling.. *Blood*, **2009**, 114, 759-759	2.2	3
78	An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory **2021**,		3
77	Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.. *Cancer Research*, **2022**,	10.1	2
76	Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas.. *Blood*, **2006**, 108, 2716-2716	2.2	2
75	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. *Blood*, **2007**, 110, 52-52	2.2	2
74	NF-B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome. *Blood*, **2010**, 116, 144-144	2.2	2
73	Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM. *Blood*, **2013**, 122, 1768-1768	2.2	2
72	In Situ Vaccination with a TLR9 Agonist and Anti-OX40 Antibody Leads to Tumor Regression and Induces Abscopal Responses in Murine Lymphoma. *Blood*, **2016**, 128, 1847-1847	2.2	2
71	Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.. *Journal of Clinical Oncology*, **2016**, 34, 7511-7511	2.2	2

70	Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. *Cell Chemical Biology*, **2021**,	8.2	2
69	Charge-Altering Releasable Transporters Enable Specific Phenotypic Manipulation of Resting Primary Natural Killer Cells		2
68	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. *OncoImmunology*, **2016**, 5, e1186323	7.2	2
67	A brief personal history of cancer immunotherapy at Stanford: if these walls could talk *Immunologic Research*, **2014**, 58, 277-81	4.3	1
66	Identification of peptide ligands for the antigen binding receptor expressed on human B-cell lymphomas. *Methods in Molecular Biology*, **1998**, 87, 209-34	1.4	1
65	Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation. *Blood*, **2019**, 134, 84-84	2.2	1
64	Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination. *Blood*, **2020**, 136, 36-37	2.2	1
63	Paraffin-Based 6-Gene Model Predicts Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.. *Blood*, **2007**, 110, 49-49	2.2	1
62	Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts.. *Blood*, **2009**, 114, 2716-2716	2.2	1
61	Immunotransplant Expands Vaccine-Induced Memory T Cell Responses In Patients With Mantle Cell Lymphoma. *Blood*, **2013**, 122, 1816-1816	2.2	1
60	Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies. *Blood*, **2013**, 122, 4417-4417	2.2	1
59	B-Cell Receptors Of Follicular Lymphoma Patients Recognize Themselves. *Blood*, **2013**, 122, 633-633	2.2	1
58	Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation. *Blood*, **2014**, 124, 4487-4487	2.2	1
57	DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. *Blood*, **2016**, 128, 2686-2686	2.2	1
56	Identification of Tigit on Intra-Tumor T Cells As a New Target for Immune Checkpoint Blockade in Follicular Lymphoma. *Blood*, **2016**, 128, 917-917	2.2	1
55	An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.. *Journal of Clinical Oncology*, **2013**, 31, TPS8614-TPS8614	2.2	1
54	Immunoglobulin G Fc Polymorphism Is Correlated with Rituximab-Induced Neutropenia Following Autologous Hematopoietic Cell Transplantation.. *Blood*, **2004**, 104, 442-442	2.2	1
53	In Situ Vaccination with Cpg and Anti-OX40 Antibody: Preclinical Optimization for Clinical Translation. *Blood*, **2018**, 132, 2943-2943	2.2	1

52	Noninvasive molecular subtyping and risk stratification of DLBCL.. *Journal of Clinical Oncology*, **2016**, 34, 7554-7554	2.2	1
51	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. *Blood*, **2016**, 128, 2930-2930	2.2	1
50	Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.. *Blood*, **2009**, 114, 622-622	2.2	1
49	In Situ Vaccination with IL-12Fc and TLR Agonist - a Crucial Role for B Cells in Generating Anti-Tumor T Cell Immunity. *Blood*, **2021**, 138, 3514-3514	2.2	0
48	Cell-Free Technology for Rapid Production of Patient-Specific Fusion Protein Vaccines69-82		
47	Cytokine fusion constructs as DNA vaccines against tumors. *Methods in Molecular Medicine*, **2000**, 29, 221-39		
46	Somatic mutations in the Ig VH genes of human B cell lymphoma. *Pediatrics International*, **1987**, 29, 561-5	1.2	
45	Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation. *Blood*, **2021**, 138, 3539-3539	2.2	
44	In Situ Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions. *Blood*, **2021**, 138, 2407-2407	2.2	
43	Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. *Blood*, **2021**, 138, 2064-2064	2.2	
42	The Percentage of Tumor-Infiltrating T Cells Is Not Correlated with Overall Survival in Follicular B-Cell Lymphomas.. *Blood*, **2004**, 104, 3262-3262	2.2	
41	Immunoglobulin G Fc Receptor Polymorphisms and Clinical Course in Follicular Lymphoma Patients.. *Blood*, **2004**, 104, 3250-3250	2.2	
40	A Novel Method for Producing Custom-Made Idiotype Vaccines for Lymphoma Immunotherapy Using a Cell-Free Expression System.. *Blood*, **2004**, 104, 1410-1410	2.2	
39	CpG in the Immunotherapy of B-Cell Lymphoma.. *Blood*, **2005**, 106, 344-344	2.2	
38	Expression of the Human Germinal Center Associated Lymphoma (HGAL) Protein Identifies a Subset of Classical Hodgkin Lymphoma of Germinal Center Derivation and Improved Outcome.. *Blood*, **2005**, 106, 23-23	2.2	
37	Anti-Tumor Effect of Direct Intratumor Injection of Recombinant Fowlpox Virus Encoding CD40 Ligand in B Cell Lymphoma Model.. *Blood*, **2005**, 106, 1477-1477	2.2	
36	RNA-Binding Protein VICKZ Is Expressed in a Germinal Center Associated Pattern among Lymphoma Subtypes.. *Blood*, **2005**, 106, 1909-1909	2.2	
35	The Oncoprotein LMO2 Is Expressed in a Germinal Center B-Cell-Associated Pattern and Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. *Blood*, **2006**, 108, 810-810	2.2	

34	Preferential Proliferation of T Effectors and Tumor Protection by Adoptive Transfer of Primed Anti-Lymphoma Splenocytes into Lymphodepleted Hosts.. *Blood*, **2007**, 110, 2753-2753	2.2
33	Anti-Idiotype Antibody Response after Vaccination Correlates with Better Overall Survival in Follicular Lymphoma.. *Blood*, **2007**, 110, 647-647	2.2
32	Gene-Specific Delineation of Copy Number Aberrations in Follicular Lymphoma with Molecular Inversion Probes.. *Blood*, **2007**, 110, 2603-2603	2.2
31	Correlation of IFN□CD107 and CD137 at the Single Cell Level Can Be Used To Monitor T Cell Responses in Patients after Immunotherapy.. *Blood*, **2007**, 110, 2306-2306	2.2
30	Efficient Transfer of CD40L mRNA into Mantle Cell Lymphoma for the Production of a Whole Tumor Cell Vaccine.. *Blood*, **2007**, 110, 2591-2591	2.2
29	The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms with rare exceptions. *FASEB Journal*, **2008**, 22, 902.15	0.9
28	Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma. *Blood*, **2018**, 132, 1612-1612	2.2
27	Single Cell RNA Sequencing of Serial Tumor and Blood Biopsies from Lymphoma Patients on an in Situ Vaccination Clinical Trial. *Blood*, **2018**, 132, 4107-4107	2.2
26	A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma. *Blood*, **2019**, 134, 2825-2825	2.2
25	Dynamic Immune Modulation Seen By Single Cell RNA-Sequencing of Serial Lymphoma Biopsies in Patients Undergoing in Situ Vaccination. *Blood*, **2019**, 134, 1479-1479	2.2
24	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.. *Journal of Clinical Oncology*, **2014**, 32, 8504-8504	2.2
23	Generating Chimeric Antigen Receptors Utilizing Novel Anti-CD3 Nanobeads. *Blood*, **2014**, 124, 5949-5949	2.2
22	Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).. *Journal of Clinical Oncology*, **2015**, 33, 8539-8539	2.2
21	Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.. *Journal of Clinical Oncology*, **2015**, 33, 8570-8570	2.2
20	T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC. *Blood*, **2015**, 126, 2228-2228	2.2
19	Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN. *Blood*, **2015**, 126, 1539-1539	2.2
18	Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients. *Blood*, **2016**, 128, 2947-2947	2.2
17	Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. *Blood*, **2016**, 128, 4107-4107	2.2

List of Publications

16	Treating B Cell Lymphomas with Anti CD81 Antibodies. *Blood*, **2016**, 128, 4180-4180	2.2
15	Massively Parallel Single Cell RNA-Seq of Primary Lymphomas Reveals Distinct Cellular Lineages and Diverse, Intratumoral Transcriptional States. *Blood*, **2016**, 128, 1090-1090	2.2
14	Adoptive Cell Therapy for Lymphoma: Use of CpG-Loaded Tumor Cells to Generate Potent Anti-Tumor CD4 T Cell Immunity.. *Blood*, **2009**, 114, 929-929	2.2
13	Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma.. *Blood*, **2009**, 114, 2951-2951	2.2
12	Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma.. *Blood*, **2009**, 114, 2712-2712	2.2
11	Adoptive Therapy for Lymphoma with CD4 Memory T Cells Depleted of CD137-Expressing Tregs.. *Blood*, **2009**, 114, 1693-1693	2.2
10	Clinical Translation of a Prognostic Follicular Lymphoma Signaling Profile. *Blood*, **2010**, 116, 636-636	2.2
9	CD137 Identifies a Population of Regulatory T Cells That Inhibit Anti-Tumor Immune Responses In Adoptive Immunotherapy. *Blood*, **2010**, 116, 2093-2093	2.2
8	Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. *Blood*, **2010**, 116, 3134-3134	2.2
7	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. *Blood*, **2010**, 116, 2006-2006	2.2
6	Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. *Blood*, **2011**, 118, 3068-3068	2.2
5	in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses. *Blood*, **2012**, 120, 3703-3703	2.2
4	Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy. *Blood*, **2012**, 120, 3713-3713	2.2
3	Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma. *Blood*, **2012**, 120, 148-148	2.2
2	High-Throughput Sequencing Of T Cell Receptors Detects Signatures Of T Cell Repertoire That Predict MRD Status In Patients With Mantle Cell Lymphoma Undergoing Immunotransplantation. *Blood*, **2013**, 122, 4251-4251	2.2
1	Vaccines in lymphoma. *Clinical Advances in Hematology and Oncology*, **2004**, 2, 424, 427	0.6